UNION therapeutics appoints Dr. Kim Kjoeller as Chief Executive Officer and further strengthens leadership by appointing Dr. Günter Ditzinger as Chief Technology Officer
UNION strengthens leadership following expansion of clinical pipeline from one to five later stage clinical candidates during 2020 Dr. Kim Domela Kjoeller, Executive Vice President Global Research & Development at […]
Danish biotech UNION adds program to prevent COVID-19 with intranasal delivery of niclosamide.
· Niclosamide is a potent inhibitor of SARS-CoV-2 with potency >40x higher than remdesivir as demonstrated by Institut Pasteur Korea
· The sinonasal cavity is considered a major site of early infection by SARS-CoV-2 and a major factor in transmission.
· Intranasal administration of niclosamide has been demonstrated to prevent fatal outcomes in a murine challenge model
· UNI91103 is a nasal spray pump delivering a concentrated niclosamide salt solution to the nasal cavity
· UNI91103 has been tested in 44 healthy volunteers with positive results
· UNI91103 is being prepared for clinical trials in subjects at high risk of contracting COVID-19
UNION therapeutics A/S completes dosing of healthy volunteers with UNI911 (inhaled niclosamide) for COVID-19
UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911 UNION has utilized many years of experience with niclosamide to develop UNI911, a […]
UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.
Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has advanced niclosamide-based program for COVID-19 (UNI911) to clinical development, currently […]
Spatial and Temporal Dynamics of SARS-CoV-2 in COVID-19 Patients – A Systematic Review and Meta-Analysis Published in EBioMedicine
Hellerup, Denmark: UNION therapeutics A/S today announced the publication of a systematic review and meta-analysis of COVID-19 patient’s presence and duration of SARS-CoV-2 virus published in EBioMedicine under The Lancet. The main […]
UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2
Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become ‘best-in-class’ based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical) PDE4 compound series strengthens […]
The Journal of Investigative Dermatology Publish UNION therapeutics’ Phase 2 Clinical Trial Results
ATx201 modulates biomarkers of cutaneous inflammation and skin barrier function in patients with moderate atopic dermatitis Analysis of safety data revealed ATx201 generally safe and well-tolerated in subjects with moderate […]
UNION receives approval from Danish Medicines Agency to initiate clinical study with niclosamide for treatment of COVID-19
Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has leveraged existing deep knowledge of niclosamide, derivatives and […]
UNION therapeutics launches COVID-19 program in collaboration with Institut Pasteur Korea
Niclosamide identified as the most potent FDA approved inhibitor of SARS-Cov-2 by Institut Pasteur Korea Potency of niclosamide >25x higher than chloroquine and >40x higher than remdesivir UNION has extensive […]
UNION initiates Phase 2b Dose-Ranging Study Evaluating ATx201 OINTMENT in Patients with Mild-to-Moderate Atopic Dermatitis
Multi-national, double-blinded, and vehicle-controlled study Study expected to enroll approximately 210 patients COPENHAGEN, Denmark: UNION therapeutics A/S (“UNION”), a privately held clinical stage pharmaceutical company dedicated to the discovery and […]